Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on September 1, 2021. The filing discloses a material definitive agreement entered into on the same date with Melt Pharmaceuticals, Inc., a company in which Harrow owns approximately 44% of the equity interests.
Key Financial Metrics and Transaction Details
The filing details a specific loan transaction rather than general operating results. Key metrics for this transaction include:
- Principal Amount: $13,500,000 (fully funded at closing).
- Interest Rate: 12.50% per annum.
- Interest Payment Terms: Borrower may pay interest in kind (PIK) at its option until maturity.
- Maturity Date: September 1, 2022.
- Security: The loan is secured by a security interest in substantially all of Melt Pharmaceuticals' personal property, rights, and assets, including intellectual property.
The filing text does not provide clear values for Harrow Health's consolidated revenue, profit, cash flow, margins, or total debt levels outside of this specific transaction.
Material Changes and Agreements
The primary material change is the creation of a direct financial obligation and a new asset (the loan receivable) on Harrow's balance sheet. Additionally, the parties entered into a Right of First Refusal Agreement granting Harrow the right to match any offer received by Melt Pharmaceuticals regarding the commercial rights to its drug candidates for a period of five years.
Outlook, Risks, and Covenants
The Loan Agreement includes customary covenants limiting Melt Pharmaceuticals' ability to incur additional indebtedness, create liens, or engage in mergers and acquisitions without consent. An event of default allows Harrow to declare all amounts immediately due and payable and increases the interest rate by 3% per annum. The filing notes that the loan is secured by the borrower's assets, mitigating some credit risk, but the borrower's ability to repay depends on its future performance.
Key Facts for Investor Verification
- Verify the impact of the $13.5 million loan on Harrow's liquidity and cash flow statements in subsequent filings.
- Monitor Melt Pharmaceuticals' progress on drug candidates to assess the value of the Right of First Refusal.
- Confirm whether interest payments are made in cash or accrued as PIK in future quarterly reports.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for specific default triggers and covenants.